Working… Menu

Oral ISL QM as PrEP in Cisgender Women at High Risk for HIV-1 Infection (MK-8591-022) (Impower-022)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04644029
Recruitment Status : Recruiting
First Posted : November 25, 2020
Last Update Posted : April 23, 2021
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : July 5, 2024
Estimated Study Completion Date : July 5, 2024